

University of Groningen

## Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy

Kol, Klaas Jan-Derk

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2019

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Kol, K. J-D. (2019). *Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy*. Rijksuniversiteit Groningen.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

# **Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy**

**Arjan Kol**

Kol, K.J.

**Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy**

Thesis, University of Groningen, Groningen, The Netherlands

**ISBN:** 978-94-034-1339-6

**ISBN (electronic version):** 978-94-034-1338-9

© K.J. Kol, 2018

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanically, by photocopying, recording, or otherwise, without prior written permission of the author.

Cover: Photo by Danique Giesen.

Printing by: Ipskamp Printing, Enschede, The Netherlands.

The research presented in this thesis was financially supported by European Research Council (ERC) advanced grant 293445, OnQview, a Roche Innovation Fund grant, a POINTING grant of the Dutch Cancer Society and a De Cock Stichting grant.

**Printing of this thesis was supported by:**



**umcg**

Graduate School of  
Medical Sciences

Stichting Werkgroep  
Interne Oncologie



**rijksuniversiteit  
groningen**



rijksuniversiteit  
groningen

# **Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy**

**Proefschrift**

ter verkrijging van de graad van doctor aan de  
Rijksuniversiteit Groningen  
op gezag van de  
rector magnificus prof. dr. E. Sterken  
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 30 januari 2019 om 12.45 uur

door

**Klaas Jan-Derk Kol**

geboren op 2 augustus 1988  
te Ten Boer

**Promotores:**

Prof. dr. S. de Jong

Prof. dr. E.G.E. de Vries

**Copromotores:**

Dr. A.G.T. Terwisscha van Scheltinga

**Beoordelingscommissie:**

Prof. dr. N.H. Hendrikse

Prof. dr. H.J.M. Groen

Prof. dr. F.A.E. Kruyt

**Paranimfen:**

Martin Pool

Thijs Stutvoet



# CONTENTS

---

<b>Chapter 1</b>	General introduction and outline of thesis	9
<b>Chapter 2</b>	AOC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells Oncotarget. 2017;8:45432-45446	19
<b>Chapter 3</b>	Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer <sup>89</sup> Zr-imgatuzumab Oncotarget. 2016 18:7:68111-68121	49
<b>Chapter 4</b>	HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting Pharmacol Ther. 2014;143:1-11	69
<b>Chapter 5</b>	<sup>89</sup> Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment MAbs. 2017;9:1370-1378	99
<b>Chapter 6</b>	MAPK pathway activity plays a key role in programmed death ligand-1 expression of EGFR wild-type lung adenocarcinoma cells Submitted	121
<b>Chapter 7</b>	Summary, general discussion and future perspectives	149
<b>Chapter 8</b>	Nederlandse samenvatting (summary in Dutch)	163
<b>Appendix I</b>	Dankwoord (acknowledgements)	171



